An Open Label, Phase 2 Trial of Orally Administered Bosutinib (SKI-606) in Adult Patients With Recurrent Glioblastoma (GBM)
- Arm A: Participants will receive daily doses of bosutinib orally for 7-9 days prior to
surgery. On the day of the scheduled surgery (either craniotomy or surgical resection as
planned by the treating doctor), participants will take the bosutinib within 6-12 hours of
the surgery. During the surgery, tissue samples of the tumor will be collected to test the
levels of bosutinib in the brain. A contrast-enhanced MRI or CT scan will be done within
days after the surgery. Daily dosing of bosutinib will resume after a recovery period of 10
days. From then on, the study will be divided into 28-day cycles.
The following tests/procedures will be performed regularly during cycles of study treatment:
medical history; physical exam; blood tests; contrast-enhanced CT or MRI scans (even
numbered cycles only).
- Arm B: Participants will receive daily doses of bosutinib. The study is divided int
28-day cycles. There are no breaks from taking bosutinib between treatment cycles. The
following tests/procedures will be performed regularly during cycles of study
treatment: medical history; physical exam; blood tests; contrast-enhanced CT or MRI
scans (even numbered cycles only).
- Participants may continue to receive daily bosutinib until their disease worsens, they
experience unmanageable side-effects, or they decide to stop treatment.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-Free Survival
Assess progression-free survival at six months in patients with recurrent GBM at first or second recurrence who are treated with continuous daily dosing of bosutinib (Arm B)
2 years
No
Tracy Batchelor, MD
Principal Investigator
Massachusetts General Hospital
United States: Food and Drug Administration
10-190
NCT01331291
April 2011
October 2012
Name | Location |
---|---|
Massachusetts General Hospital | Boston, Massachusetts 02114-2617 |
Dana=Farber Cancer Institute | Boston, Massachusetts 02115 |